Canopy Growth (CGC) Debt Ratio (2017 - 2026)

Canopy Growth (CGC) posted Debt Ratio of 0.21 for Q1 2026, up 2.56% sequentially from 0.2 in Q4 2025, and down 37.05% YoY from 0.33 in Q1 2025.

Canopy Growth (CGC) Debt Ratio (2017 - 2026) Analysis & Trends

Canopy Growth has reported Debt Ratio for 10 years, with the latest figure at 0.21 in Q1 2026.

Quarterly Debt Ratio fell 37.05% year-over-year to 0.21 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.21 (down 37.05% YoY) and the FY2026 annual result came in at 0.21, down 37.05% from the prior year.
Debt Ratio climbed to 0.21 in Q1 2026 per CGC's latest filing, from 0.2 in the prior quarter.
Over five years, Debt Ratio peaked at 0.54 in Q1 2023 and troughed at 0.2 in Q4 2025.
A 5-year average of 0.38 and a median of 0.41 in 2023 frame the typical range for Debt Ratio.
The sharpest annual moves came in 2023 and 2025: Debt Ratio jumped 100.04% in 2023, then slumped 52.54% in 2025.
Over 5 years, Debt Ratio stood at 0.41 in 2022, then gained by 9.75% to 0.45 in 2023, then slipped by 15.74% to 0.38 in 2024, then sank by 46.38% to 0.2 in 2025, then grew by 2.56% to 0.21 in 2026.
According to Business Quant data, Debt Ratio over the past three periods registered 0.21, 0.2, and 0.21 for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Haleon	43.85 Bn	42.88 Bn	-	-0.13
2	Teva Pharmaceutical Industries	43.02 Bn	39.37 Bn	2.15 Bn	0.42
3	Zoetis	31.47 Bn	29.79 Bn	1.05 Bn	0.60
4	Takeda Pharmaceutical	28.59 Bn	22.79 Bn	5.10 Bn	0.32
5	United Therapeutics	22.20 Bn	19.53 Bn	683.80 Mn	-
6	Viatris	18.76 Bn	17.87 Bn	1.46 Bn	0.38
7	Neurocrine Biosciences	15.45 Bn	15.06 Bn	935.80 Mn	-
8	Elanco Animal Health	11.76 Bn	11.23 Bn	798.00 Mn	0.29
9	Dr Reddys Laboratories	10.10 Bn	9.94 Bn	-	0.12
10	Canopy Growth	442.95 Mn	195.94 Mn	16.08 Mn	0.22

Download Data